In addition to QuANTUM-R (described above), quizartinib is being evaluated in QuANTUM-First, a global, randomized, double-blind, placebo-controlled, phase 3 study (NCT02668653) examining the effect of quizartinib plus standard induction and consolidation chemotherapy followed by single-agent quizartinib on EFS in patients with newly diagnosed primary FLT3-ITD-mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.